​In year two of the Trump administration, healthcare leaders will be adjusting their strategies to focus on investments, collaborations and efficiencies that build enterprise resilience on a baseline of continued uncertainty. Healthcare players, including the White House, Congress, state lawmakers, industry groups and patient advocates, will continue to parry, feint and thrust, which will likely result in additional policy changes. Healthcare providers and insurers in particular should anticipate the changes as they come.

Beyond health reform, additional risks and uncertainties are moving to center stage, as is the consumer, and the health industry is being forced to act.

Featured Speakers:

Gurpreet Singh

Management Consulting and Strategy Leader
PwC

Gurpreet is a Partner and the leader for the Management Consulting and Strategy competency in Health Industries (Payer, Provider and Pharma/Life Sciences) at PwC. He is responsible for delivering strategies that enhance growth, improve financial performance and leverage emerging technologies to gain competitive advantage. He has expertise in Pharma & Life Sciences Research and Development, Pharma commercial operations (sales & marketing), patient outcomes/Real World Evidence and Information Technology/Digital Strategies that drive innovation.

Karen Young

US Pharmaceutical and Life Sciences Sector Leader
PwC

Karen is currently the US Pharmaceutical and Life Sciences Leader. As the Pharma and Life Sciences leader, Karen is charged with setting the strategy for the firm’s practice across Audit, Tax and Advisory. She leads over 3,000 professionals in delivering against that strategy with the highest level of client service and thought leadership working within our global network to achieve results. Karen has served many pharmaceutical and life sciences clients. She specializes in the areas of acquisitions, divestitures, strategic alliances, pharmaceutical gross-to-net issues and tax structuring. Responsibilities have included leading large multi-national and domestic SEC audits, internal audit and advisory engagements.

Ben Isgur

Health Research Institute Leader
PwC

Benjamin Isgur leads PwC's Health Research Institute. HRI is a dedicated research group that provides new intelligence, perspective, and analysis on major health-related business issues. In this role, he oversees thought leadership and research initiatives for the firm and clients. He also consults with healthcare systems, trade associations, and policy groups on strategic planning, and industry intelligence and trends. Ben is a published writer and his research is often cited by health leaders across the industry.

Trine Tsouderos

Health Research Institute Regulatory Center Leader
PwC

Trine Tsouderos is a director at PwC’s Health Research Institute (HRI), where she develops national thought leadership on the healthcare industry's new entrants and innovators such as PwC’s report, Healthcare’s new entrants: Who will be the industry’s Amazon.com? A former journalist, Trine has 17 years of newsroom experience. Most recently, she was medical reporter at the Chicago Tribune, winning state and national awards for her work. Trine is also a seasoned panel moderator and speaker, and her work has been cited in books and scientific papers.

Ben Comer

Senior Manager, Health Research Institute
PwC

Ben Comer is a senior manager at PwC's Health Research Institute (HRI), where he focuses on business and social issues impacting the biopharmaceutical and life sciences industries. Ben also contributes writing and research to cross-sector health policy projects developed by the Institute. Prior to joining HRI, Ben worked as a New York City-based journalist covering the pharmaceutical and biotech industries. Ben was most recently senior editor at Pharmaceutical Executive magazine, an award-winning industry publication, and has written on a wide range of pharmaceutical and health topics for a number of media outlets.

NOW AVAILABLE ON-DEMAND